Treatment with antidepressants is ...

Treatment with antidepressants is the main therapeutic intervention, regardless of the nosology of depression, which includes the full range of mental illnesses. The choice of antidepressant is determined primarily by the psychopathological picture of depression. Widely accepted so far is confirmed by clinical experience the principle of appointment of certain antidepressants, depending on the type of depression, and predominant expression of its major symptoms. Currently, the concept is gaining recognition prediction performance of antidepressant therapy [14], based on an analysis of the relation of symptom positive and negative affectivity, ie representation of the phenomena of depression depression and anxiety, on the one hand, and the phenomena of alienation, apathy, anhedonia, psychic anesthesia with another. Despite the emergence of a large number of various new antidepressants is certainly safe and effective enough, do not lose their meaning long and well-known drugs for the treatment of depression and, moreover, they called again an active interest of researchers and practitioners. These medicines include the antidepressant domestic Pirazidol, jointly developed by more than 30 years ago, pharmacologists and psychiatrists VNIHFI Institute of Psychiatry RF Ministry of Health. For nearly 20 years, the drug has been used successfully for the treatment of depression to the point, both in connection with the economic situation of its production was halted and then resumed after a ten-year hiatus in 2002. Lack Pirazidola in the pharmaceutical market was very tangible for physicians and patients because this antidepressant had a special place on the specifics of their clinical action, tolerability, and possible appointment in certain types of somatic pathology (glaucoma, prostate adenoma), is a contraindication to many antidepressants. Pirazidol (pirlindol) is one of the first representatives of the selective reversible monoamine oxidase inhibitors. The activity of this enzyme is restored within a few hours, in connection with which the drug does not cause tyramine reactions. According to its chemical structure it refers to a group chetyrehtsiklicheskih antidepressants. Pirazidol reveals an original mechanism of action, possessing the ability to simultaneously inhibit the activity of MAO, and block the path of the metabolic destruction of monoamines selectively dezaminiruya serotonin and epinephrine. Thereby affecting the well-known to date, the neurochemical mechanisms of depression, the drug sells its antidepressant properties. Pirazidol rapidly absorbed, absorption slows down meal. Bioavailability of 20-30%. More than 95% of the drug binds to plasma proteins. The main pathway - kidney. Pharmacokinetics Pirazidola not detect a linear dose-dependent. The half-life of the drug varies from 1,7 to 3,0 hours.